SCINOPHARM TAIWAN
GenericsSCINOPHARM TAIWAN is a generic drug manufacturer focused on Neurology, Oncology, Cardiovascular.
SCINOPHARM TAIWAN's Key Drugs
SCINOPHARM TAIWAN's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
SCINOPHARM TAIWAN's Recent FDA Approvals
New NDA/BLA approvals for SCINOPHARM TAIWAN over the last two years — novel drugs only, excluding generics and label supplements.
SCINOPHARM TAIWAN's Therapeutic Areas
SCINOPHARM TAIWAN's approved drugs and pipeline span 4 therapeutic areas, led by Neurology and Oncology. Weighted by commercial stage — approved drugs count most, then late-stage trials.
SCINOPHARM TAIWAN's Top Competitors
SCINOPHARM TAIWAN's closest competitors by therapeutic-area and drug-target overlap include Novartis, GE HEALTHCARE, and Merck. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
SCINOPHARM TAIWAN Pipeline Snapshot
Active clinical trials for SCINOPHARM TAIWAN across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Neurology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2006-04-17
- Latest
- 2025-12-31
- Applications
- 5